NIH Study Banks Cord Blood Stem Cells to Unlock Sickle Cell Cures
NHLBI researchers optimize collection and storage of umbilical cord blood from sickle cell-affected and healthy newborns for future stem cell therapies.
Summary
This completed NIH clinical trial developed protocols for collecting, processing, and storing umbilical cord blood from newborns with sickle cell disease, sickle cell trait, and unaffected babies. Cord blood is exceptionally rich in hematopoietic stem cells, which hold promise for treating sickle cell disease through transplantation or gene therapy. Because cord blood from these three groups may behave differently in laboratory and clinical settings, researchers needed to establish optimized handling procedures for each. Blood was tested for infectious diseases, genotyped for the sickle cell gene, tissue typed, and then frozen. Samples from affected babies were stored indefinitely for potential future treatment of the child, while trait or normal samples were stored up to three years for possible use in treating a sibling. The study laid essential groundwork for cord blood banking programs targeting sickle cell disease.
Detailed Summary
Sickle cell disease is one of the most common inherited blood disorders worldwide, affecting millions and causing lifelong organ damage through abnormal red blood cell sickling and vascular obstruction. Despite decades of research, curative options remain limited. Stem cell transplantation and emerging gene therapies represent the most promising paths to a cure, and umbilical cord blood is an ideal stem cell source given its immaturity and immunological flexibility. This study addressed a critical early barrier: establishing the best methods to collect, process, and preserve cord blood from newborns across three distinct groups — those with sickle cell disease, those with sickle cell trait, and unaffected babies.
The trial, sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and completed at the NIH, enrolled pregnant women aged 18 to 45 who were either at risk of delivering a baby with sickle cell disease or were healthy volunteers. After delivery, cord and placental blood was collected, tested for infectious diseases, and in at-risk pregnancies also genotyped and tissue typed. Samples were then cryopreserved according to the baby's diagnosis.
For babies diagnosed with sickle cell disease, cord blood was banked indefinitely as a potential future treatment resource for that child, whether via stem cell transplant or gene therapy. For babies with sickle cell trait or normal hemoglobin, blood was stored for up to three years as a possible sibling donor source, with participants choosing subsequent disposition of unused samples.
The study produced no clinical treatment outcomes — its purpose was methodological standardization and biobanking rather than therapeutic intervention. However, its implications are significant: optimized cord blood banking protocols directly enable future transplantation and gene therapy trials for sickle cell disease.
Key caveats include the study's early date (initiated 2001), meaning stored samples and protocols may not reflect current best practices. Additionally, since no abstract results data were published, the specific processing and viability outcomes remain unclear from available information.
Key Findings
- Cord blood from sickle cell disease, sickle cell trait, and normal babies requires separate optimized processing protocols.
- Affected newborns' cord blood was stored indefinitely for potential future stem cell transplantation or gene therapy.
- Trait or normal sibling cord blood was banked up to 3 years as a matched donor reserve for affected siblings.
- All samples were tested for infectious disease, genotyped, and tissue typed before cryopreservation.
- The study established NIH-approved biobanking infrastructure critical to advancing sickle cell curative therapies.
Methodology
Prospective collection study enrolling pregnant women aged 18–45 at risk for sickle cell-affected deliveries and healthy controls. Cord and placental blood was collected post-delivery, tested, genotyped, tissue typed, and cryopreserved using group-specific protocols. Participants and their physicians were followed biannually for infant health updates.
Study Limitations
This summary is based on the abstract and study registration only, as the full results are not openly available; specific processing outcomes and viability metrics cannot be assessed. The study was initiated in 2001, and its protocols may not reflect current state-of-the-art cord blood banking and cryopreservation techniques. No clinical treatment endpoints were included, limiting direct conclusions about therapeutic efficacy.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.